A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin LymphomaJesús G. Berdeja, Sagar Lonial, Shambavi Richard et al.|Blood|2021Cited by 22
Abstract CT186: Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MMSagar Lonial, Jesus Bardeja, Shambavi Richard et al.|Cancer Research|2022Cited by 11
Abstract 4631: Evaluation of the impact of homozygous MTAP truncations on the activity and selectivity of MTA-cooperative PRMT5 inhibitorsMatthew R. Tonini, Kimberly J. Briggs, André A. Mignault et al.|Cancer Research|2024Cited by 1
Abstract 4608: Evaluation of the impact of homozygous MTAP truncations on the clinical activity of MTA-cooperative PRMT5 inhibitorsKimberly J. Briggs, Adam Crystal, Andre Mignault et al.|Cancer Research|2025Cited by 0